Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00038610
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
- Conditions
- Meningeal Neoplasms
- First Posted Date
- 2002-01-16
- Last Posted Date
- 2007-02-28
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00029523
- Locations
- 🇺🇸
Straub Clinic and Hospital, Honolulu, Hawaii, United States
🇺🇸Georgetown University Medical Center Hematology/Oncology, Washington, District of Columbia, United States
🇺🇸Loyola University Medical Center, Dept. of Hematology/Oncology, Maywood, Illinois, United States
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
- Conditions
- HIV InfectionsLymphoma, Non-Hodgkin
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 250
- Registration Number
- NCT00000658
- Locations
- 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸USC CRS, Los Angeles, California, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
- Conditions
- Lymphoma, Non-HodgkinHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-01
- Target Recruit Count
- 33
- Registration Number
- NCT00000801
- Locations
- 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
- Conditions
- Lymphoma, Non-HodgkinHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 45
- Registration Number
- NCT00000703
- Locations
- 🇺🇸
Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
- Conditions
- HIV InfectionsLeukoencephalopathy, Progressive Multifocal
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00001048
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
- Conditions
- Lymphoma, Non-HodgkinHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 18
- Registration Number
- NCT00000689
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
- Conditions
- Lupus Erythematosus, Systemic
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 10
- Registration Number
- NCT00004643
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.